Orexo 관리

관리 기준 확인 3/4

Orexo CEO는 Nikolaj Sorensen, Feb2013 에 임명되었습니다 의 임기는 11.75 년입니다. 총 연간 보상은 SEK 6.12M, 59.5% 로 구성됩니다. 59.5% 급여 및 40.5% 보너스(회사 주식 및 옵션 포함). 는 € 145.63K 가치에 해당하는 회사 주식의 0.52% 직접 소유합니다. 145.63K. 경영진과 이사회의 평균 재임 기간은 각각 5.8 년과 4.6 년입니다.

주요 정보

Nikolaj Sorensen

최고 경영자

SEK 6.1m

총 보상

CEO 급여 비율	59.5%
CEO 임기	11.8yrs
CEO 소유권	0.5%
경영진 평균 재임 기간	5.8yrs
이사회 평균 재임 기간	4.6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Nikolaj Sorensen 의 보수는 Orexo 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-SEK 105m
Jun 30 2024	n/a	n/a	-SEK 97m
Mar 31 2024	n/a	n/a	-SEK 73m
Dec 31 2023	SEK 6m	SEK 4m	-SEK 128m
Sep 30 2023	n/a	n/a	-SEK 201m
Jun 30 2023	n/a	n/a	-SEK 195m
Mar 31 2023	n/a	n/a	-SEK 218m
Dec 31 2022	SEK 6m	SEK 4m	-SEK 178m
Sep 30 2022	n/a	n/a	-SEK 152m
Jun 30 2022	n/a	n/a	-SEK 177m
Mar 31 2022	n/a	n/a	-SEK 216m
Dec 31 2021	SEK 10m	SEK 4m	-SEK 223m
Sep 30 2021	n/a	n/a	-SEK 207m
Jun 30 2021	n/a	n/a	-SEK 240m
Mar 31 2021	n/a	n/a	-SEK 198m
Dec 31 2020	SEK 9m	SEK 3m	-SEK 84m
Sep 30 2020	n/a	n/a	SEK 4m
Jun 30 2020	n/a	n/a	SEK 201m
Mar 31 2020	n/a	n/a	SEK 288m
Dec 31 2019	SEK 6m	SEK 3m	SEK 219m
Sep 30 2019	n/a	n/a	SEK 232m
Jun 30 2019	n/a	n/a	SEK 182m
Mar 31 2019	n/a	n/a	SEK 178m
Dec 31 2018	SEK 5m	SEK 3m	SEK 138m
Sep 30 2018	n/a	n/a	SEK 113m
Jun 30 2018	n/a	n/a	SEK 79m
Mar 31 2018	n/a	n/a	SEK 32m
Dec 31 2017	SEK 6m	SEK 4m	SEK 23m

보상 대 시장: Nikolaj 의 총 보상 ($USD 560.19K )은 German 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 479.80K ).

보상과 수익: 회사가 수익성이 없는 동안 Nikolaj 의 보상이 증가했습니다.

CEO

Nikolaj Sorensen (52 yo)

11.8yrs

테뉴어

SEK 6,118,000

보상

Mr. Nikolaj Sørensen serves as Independent Director at Bioservo Technologies AB (publ) since May 6, 2019. He is Director at Gesynta Pharma AB. He has been the Chief Executive Officer of Orexo AB since Febr...

리더십 팀

이름	위치	테뉴어	보상	소유권
Nikolaj Sorensen	President & CEO	11.8yrs	SEK 6.12m	0.52% € 145.6k
Fredrik Jarrsten	Executive VP & CFO	2.3yrs	데이터 없음	0.076% € 21.3k
Cecilia Coupland	Senior VP & Head of Operations	5.8yrs	데이터 없음	0.042% € 11.7k
Lena Wange	Investor Relations & Communications Director	no data	데이터 없음	데이터 없음
Robert Ronn	Senior VP and Head of R&D	5.8yrs	데이터 없음	0.059% € 16.5k
Edward Kim	Chief Medical Officer	2.1yrs	데이터 없음	데이터 없음
Robert Deluca	President of Orexo US Inc	11.8yrs	데이터 없음	0.051% € 14.3k
Jesper Lind	Advisor	no data	데이터 없음	데이터 없음

5.8yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: C5G 의 관리팀은 노련하고 경험 (평균 재직 기간 5.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
George Wilkinson	Independent Director	5.6yrs	SEK 400.00k	0.056% € 15.6k
James Noble	Independent Chairman of the Board	4.6yrs	SEK 1.50m	0.19% € 52.4k
Staffan Lindstrand	Independent Director	22.8yrs	SEK 450.00k	0.099% € 27.7k
Christine Rankin	Independent Director	2.6yrs	SEK 550.00k	0.023% € 6.4k
Robin Evers	Independent Director	1.1yrs	SEK 50.00k	데이터 없음

4.6yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: C5G 의 이사회는 경험(평균 재직 기간 4.6 년)으로 간주됩니다.

Orexo 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Orexo AB (publ) Announces Nomination Committee for the Annual General Meeting 2025

Independent Chairman of the Board recently bought €24k worth of stock

Orexo AB (Publ) Announces Board Resignations

Orexo AB (publ) Announces Changes in the Board of Directors

Orexo AB (publ), Annual General Meeting, Apr 26, 2024

Orexo AB (Publ) Announces Henrik Kjær Hansen Will Resign from the Board of Directors

Recent updates

No longer forecast to breakeven

Third quarter 2024 earnings released: kr1.21 loss per share (vs kr0.97 loss in 3Q 2023)

Orexo AB (publ) Initiates New Study of OX640 in Participants with Allergic Rhinitis

Orexo AB (publ) Announces Nomination Committee for the Annual General Meeting 2025

Second quarter 2024 earnings released: kr1.04 loss per share (vs kr0.37 loss in 2Q 2023)

Orexo AB (publ) to Report Q1, 2025 Results on May 06, 2025

Independent Chairman of the Board recently bought €24k worth of stock

New minor risk - Share price stability

Orexo AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

First quarter 2024 earnings released: kr0.26 loss per share (vs kr1.86 loss in 1Q 2023)

Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US

Full year 2023 earnings released: kr3.73 loss per share (vs kr5.17 loss in FY 2022)

Orexo AB (Publ) Announces Board Resignations

New major risk - Financial position

Full year 2023 earnings released: kr3.73 loss per share (vs kr5.17 loss in FY 2022)

Orexo AB (publ) to Report Q4, 2024 Results on Feb 06, 2025

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

No longer forecast to breakeven

Third quarter 2023 earnings released

Orexo AB (publ) Announces Changes in the Board of Directors

Orexo AB (publ), Annual General Meeting, Apr 26, 2024

Orexo AB (publ) Announces Data from the MODIA Study Evaluating Impact on Use of Illicit Opioids

Orexo AB (Publ) Announces Henrik Kjær Hansen Will Resign from the Board of Directors

Orexo AB (publ) to Report Q2, 2024 Results on Jul 17, 2024

Orexo AB (publ.) Submits New Drug Application to FDA for OX124, a High-Dose Rescue Medication for Opioid Over Overio Overio Overio Overio

Second quarter 2023 earnings released

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

First quarter 2023 earnings released

Orexo AB (publ) Submits New Drug Application to FDA for OX124, A High-Dose Rescue Medication for Opioid Overdose

Full year 2022 earnings released: kr5.17 loss per share (vs kr6.51 loss in FY 2021)

Orexo AB (publ.) Initiates Exploratory Feasibility Studies of amorphOX with Two Leading Biopharmaceutical and Vaccine Companies

Orexo AB (publ) to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Third quarter 2022 earnings released

Orexo AB (publ) Announces Last Patient Enrolled in Pivotal Study Evaluating the Efficacy of MODIA® in Combination with Sublingual Buprenorphine/ Naloxone for the Treatment of OUD

Orexo AB (publ) Appoints Edward Kim, M.D., as New Chief Medical Officer

Orexo AB (publ), Annual General Meeting, Apr 18, 2023

Orexo Announces Positive Data from Phase 1 Clinical Study for OX640

Orexo AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Second quarter 2022 earnings released

Orexo AB (Publ.) Announces Successfully Initiated the First Explorative Human Clinical Study for Ox640

First quarter 2022 earnings released

Orexo AB (publ) Announces Board Appointments

Full year 2021 earnings released: kr6.51 loss per share (vs kr2.45 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Orexo AB (publ) to Report Q4, 2022 Results on Jan 26, 2023

Orexo AB (Publ.) Develops Nasal Adrenaline Medication Based on the Novel Amorphox Platform

Orexo AB Provides Information About Its New Proprietary Drug Delivery Platform - Amorphox

Third quarter 2021 earnings released: kr1.52 loss per share (vs kr2.45 loss in 3Q 2020)

Second quarter 2021 earnings released: kr2.15 loss per share (vs kr0.94 loss in 2Q 2020)

Orexo AB (Publ) Pharmaceutical Pipeline Asset Ox124 Enters Pivotal Trial

Orexo Announces First Patient Enrolled in Pivotal Study Evaluating the Efficacy of Modia™ in Combination with Sublingual Buprenorphine/ Naloxone for the Treatment of OUD

Independent Director recently bought €10k worth of stock

Independent Director recently bought €10k worth of stock

Independent Chairman of the Board recently bought €40k worth of stock

First quarter 2021 earnings released

Full year 2020 earnings released: kr2.45 loss per share (vs kr6.33 profit in FY 2019)

New 90-day low: €4.25

President & CEO recently bought €7.5k worth of stock

Orexo AB (publ) to Report Q3, 2021 Results on Nov 03, 2021

Orexo Starts to Test modiaT on Patients in Collaboration with Apexb.Io and Magellan Rx Management

Full year 2020 earnings released: kr2.45 loss per share (vs kr6.33 profit in FY 2019)

Revenue beats expectations

Orexo Strengthens IP Rights for Overdose Rescue Drug OX124

New 90-day high: €5.24

Orexo AB Enters into License and Supply Agreement with Accord Healthcare for ZUBSOLV

Revenue misses expectations

Orexo AB (Publ) Reaffirms Earnings Guidance for the Year of 2020